“nusinersen” Archives

in
Entry Author Date Location
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy 08/07/20 National
A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy 03/31/20 Raleigh Durham
Roche Challenger to Biogen’s SMA Drug Succeeds in Pivotal Study 11/11/19 National
FDA Halts Novartis Gene Therapy Study Amid Animal Safety Concerns 10/30/19 National
Bio Roundup: Biogen’s Reversal, FDA Moves Fast, a CF Cocktail & More 10/25/19 National
Bio Roundup: Leiden’s Exit, Depression Data, a New Pricing Bill & More 07/26/19 National
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease? 05/02/19 National
Biogen, Taking Its Crisis “Seriously,” Keeps Focus on Neuroscience 04/24/19 Boston
How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy 04/15/19 National
Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More 04/05/19 National
Report: Biogen, Novartis Should Drop Prices of Billon-Dollar SMA Drugs 04/04/19 Boston
Dyne Therapeutics Emerges With $50M to Take On Rare Muscle Disease 04/03/19 Boston
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
With $90M Round, Stoke Eyes a “Spinraza For Epilepsy” And a 2019 IPO 10/23/18 Boston
Spinraza Inventors Take Home $3M Breakthrough Prize in Life Sciences 10/17/18 National
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More 10/12/18 National
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More 10/05/18 National
Bio Roundup: Big Approvals, ICER Influence, Drug-Price Pushback & More 08/17/18 National
Biotech IPOs Roll On as Kiniksa, Scholar Rock Get $227M Combined 05/24/18 Boston
Bio Roundup: CRISPR Tests, Parkinson’s Questions, Opioid Bills & More 04/27/18 National
SMA Day: AveXis Gene Therapy Creeps Forward as Biogen Drug’s Sales Slow 04/25/18 Boston
Biogen Pays $1B to Broaden Ionis Pact, Betting More on RNA Drugs 04/20/18 Boston
Novartis Bets $8.7B on AveXis’s Gene Therapy for Spine Disease 04/09/18 National
Gene Therapy 2.0: New Startups Aim to Fine-Tune Gene Delivery and Control 01/04/18 Boston
15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) 12/04/17 National
Ed Kaye on Sarepta’s Duchenne Quest, Rising to CEO & His New Startup 11/20/17 Boston
Bio Roundup: GOP Drama, Immunotherapy Setbacks, Pharma Revamps 07/28/17 National
Biogen, Opening Bottlenecks, Sees Spine Drug Sales, Shares Rise 07/25/17 Boston
Duchenne, SMA, and the Rise of Patient Power at “What’s Hot” on May 11 04/27/17 Boston
Will New Data Open “Bottlenecks” For Biogen’s Pricey Spine Drug? 04/26/17 Boston
Page 1 of 2 next page »